Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study

Phase 3positivePositive

AI Analysis

Summary

BriaCell's Data Safety Monitoring Board has recommended continuation of the Phase 3 metastatic breast cancer study, indicating the trial passed interim safety review without concerns warranting early termination.

Clinical Trial Data

Phase

Phase 3

Outcome Details

Data Safety Monitoring Board recommends continuing Phase 3 metastatic breast cancer study

Importance:6/10

Sentiment:

0.60

Phase 3metastatic breast cancerDSMBclinical trial

Related Companies

$BCTX

Read the original article

Published by yahoo_finance on September 14, 2026 11:30 AM

Read Original